Acumen Pharmaceuticals, Inc.
NASDAQ: ABOS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel J. O'Connell
- Employees
- 61
- Headquarters
- Newton, United States
- IPO year
- 2021
- Market cap
- $139.9M
- Website
- https://acumenpharm.com
Loading ABOS…
Loading profile data…Frequently asked questions about ABOS
What does Acumen Pharmaceuticals, Inc. (ABOS) do?
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibod...
Where does ABOS trade?
Acumen Pharmaceuticals, Inc. (ABOS) trades on the NASDAQ Global Select.
What sector is ABOS in?
Acumen Pharmaceuticals, Inc. (ABOS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Acumen Pharmaceuticals, Inc.?
Daniel J. O'Connell is the chief executive officer of Acumen Pharmaceuticals, Inc. (ABOS).
Where is Acumen Pharmaceuticals, Inc. headquartered?
Acumen Pharmaceuticals, Inc. is headquartered in United States.
Does ABOS pay a dividend?
Acumen Pharmaceuticals, Inc. (ABOS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ABOS go public?
Acumen Pharmaceuticals, Inc. (ABOS) completed its initial public offering in 2021.